After a slow 2024, the biotech shell company Concentra Biosciences is back, offering to buy four biotechs in the past month ...

Immediately following the closing of the offer, iTeos will be acquired by Concentra, and all remaining shares not tendered in the offer, other than shares owned directly or indirectly by iTeos ...

Investing.com - Leerink Partners has lowered its price target on iTeos Therapeutics (NASDAQ: ITOS) to $10.00 from $12.00 while maintaining a Market Perform rating on the stock.

WATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. ("iTeos") (Nasdaq: ITOS) today announced that it has entered into a definitive merger agreement ...

Concentra is living up to its reputation of buying battered biotechs, swooping in to grab iTeos after the failure of its GSK-partnered TIGIT drug.

WATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (“iTeos”) (Nasdaq: ITOS) today announced that it has entered into a definitive merger ...

Immediately following the closing of the offer, iTeos will be acquired by Concentra, and all remaining shares not tendered in the offer, other than shares owned directly or indirectly by iTeos, ...

WATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. ("iTeos”) (Nasdaq: ITOS) today announced that it has entered into a definitive merger agreement ...

(RTTNews) - iTeos Therapeutics (ITOS) has entered into a definitive merger agreement whereby Concentra Biosciences, LLC will acquire iTeos for $10.047 in cash per share of iTeos common stock par ...

In related developments, Wedbush downgraded iTeos stock from Outperform to Neutral but raised the price target from $10 to $12. Piper Sandler also adjusted its price target for iTeos, reducing it ...

In related developments, Wedbush downgraded iTeos stock from Outperform to Neutral but raised the price target from $10 to $12. Piper Sandler also adjusted its price target for iTeos, reducing it from ...

Pursuant and subject to the terms of the merger agreement, Concentra will commence a tender offer by August 1, 2025, to acquire all outstanding shares of iTeos common stock for the Offer ...